Phase I/II Trial of CD3 x CD20 Bispecific Antibody Epcoritamab (GEN3013) in R/R B-Cell NHL

May 29-31, 2020; Online at meetings.asco.org/am
Epcoritamab was associated with rapid, deep responses and low-grade CRS in heavily pretreated patients with R/R NHL.
Format: Microsoft PowerPoint (.ppt)
File Size: 214 KB
Released: June 5, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AbbVie Inc.
AstraZeneca
Bristol-Myers Squibb
GlaxoSmithKline
Karyopharm Therapeutics

Related Content

In this slideset from Clinical Care Options, a panel of international experts review the role of immunotherapy for patients with endometrial cancer.

person default Mansoor Raza Mirza, MD Bradley J. Monk, MD, FACS, FACOG Prof Isabelle Ray Coquard Released: March 2, 2021

Interactive online tool providing expert treatment recommendations for newly diagnosed and relapsed/refractory follicular lymphoma from CCO

John M. Burke, MD Ian W. Flinn, MD, PhD Christopher R. Flowers, MD, MS John P. Leonard, MD Jeff P. Sharman, MD Released: March 1, 2021

Clinical Care Options (CCO) expert podcast of top leukemia presentations from Hematology 2020: magrolimab in AML, asciminib in CML (ASCEMBL), ponatinib dosing in CML (OPTIC)

Jorge Cortes, MD Eunice S. Wang, MD Released: February 26, 2021

From Clinical Care Options (CCO), Drs. Jeff Sharman and John Burke review key data from studies of lymphomas and CLL treatment presented at ASH 2020

John M. Burke, MD Jeff P. Sharman, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: February 26, 2021 Expired: February 25, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue